Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy

European Journal of Cancer

Volumn 47, Issue 17, 2011, Pages 2560-2567

  Simkens, Lieke H J ^a   Koopman, Miriam ^b   Mol, Linda ^c   Veldhuis, Gerrit Jan ^d   Ten Bokkel Huinink, Daan ^e   Muller, Erik W ^f   Derleyn, Veerle A ^g   Teerenstra, Steven ^a   Punt, Cornelis J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Integraal Kankercentrum Oost   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e DEPARTMENT OF SURGERY   (Netherlands)

^f SLINGELAND HOSPITAL   (Netherlands)

^g ELKERLIEK HOSPITAL   (Netherlands)

Author keywords

Bevacizumab; Body mass index; Chemotherapy; Colorectal cancer; Prognostic factor; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OBESITY; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80755128127     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.038     Document Type: Article

References (26)

1. P.E. O'Brien, and J.B. Dixon The extent of the problem of obesity Am J Surg 184 2002 4S 8S (Pubitemid 36071659)
2. F. Bianchini, R. Kaaks, and H. Vainio Overweight, obesity, and cancer risk Lancet Oncol 3 2002 565 574 (Pubitemid 34993644)
3. A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, and M. Zwahlen Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 371 2008 569 578 (Pubitemid 351232031)
4. J.A. Meyerhardt, P.J. Catalano, and D.G. Haller Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma Cancer 98 2003 484 495 (Pubitemid 36885987)
5. J.J. Dignam, B.N. Polite, and G. Yothers Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer J Natl Cancer Inst 98 2006 1647 1654 (Pubitemid 44811647)
6. F.A. Sinicrope, N.R. Foster, D.J. Sargent, M.J. O'Connell, and C. Rankin Obesity is an independent prognostic variable in colon cancer survivors Clin Cancer Res 16 2010 1884 1893
7. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, and M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638 (Pubitemid 36459468)
8. J.A. Meyerhardt, J.E. Tepper, and D. Niedzwiecki Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114 J Clin Oncol 22 2004 648 657 (Pubitemid 41095068)
9. J.A. Meyerhardt, D. Niedzwiecki, and D. Hollis Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803 J Clin Oncol 26 2008 4109 4115
10. E.E. Calle, and R. Kaaks Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms Nat Rev Cancer 4 2004 579 591 (Pubitemid 39025053)
11. R.J. Hunter, M.A. Navo, and P.H. Thaker Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA) Cancer Treat Rev 35 2009 69 78
12. M. Koopman, N.F. Antonini, and J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142 (Pubitemid 47042893)
13. M. Koopman, N.F. Antonini, and J. Douma Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study Ann Oncol 17 2006 1523 1528 (Pubitemid 44542038)
14. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
15. J. Tol, M. Koopman, and C.J. Rodenburg A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity Ann Oncol 19 2008 734 738 (Pubitemid 351461045)
16. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech ReP Ser 1995;854:1-452.
18. Central office for Statistics (CBS). www.statline.cbs.nl. 2004.
19. M.N. Pollak, E.S. Schernhammer, and S.E. Hankinson Insulin-like growth factors and neoplasia Nat Rev Cancer 4 2004 505 518 (Pubitemid 38868620)
20. B.M. Wolpin, J.A. Meyerhardt, and A.T. Chan Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer J Clin Oncol 27 2009 176 185
21. K. Munstedt, M. Wagner, U. Kullmer, A. Hackethal, and F.E. Franke Influence of body mass index on prognosis in gynecological malignancies Cancer Causes Control 19 2008 909 916
22. S.M. Park, M.K. Lim, S.A. Shin, and Y.H. Yun Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study J Clin Oncol 24 2006 5017 5024
23. A.S. Parker, C.M. Lohse, and J.C. Cheville Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma Urology 68 2006 741 746 (Pubitemid 44633396)
24. T. Miya, T. Goya, and H. Fujii Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11 Invest New Drugs 19 2001 61 67 (Pubitemid 32209785)
25. M. Bardou, A. Barkun, and M. Martel Effect of statin therapy on colorectal cancer Gut 59 2010 1572 1585
26. B. Guiu, J.M. Petit, and F. Bonnetain Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer Gut 59 2010 341 347